Literature DB >> 32606202

Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer.

Jeong Uk Lim1, Chang Dong Yeo1, Hyung Woo Kim1, Hye Seon Kang1, Chan Kwon Park1, Ju Sang Kim2, Jin Woo Kim1, Seung Joon Kim1,3, Sang Haak Lee1,3.   

Abstract

BACKGROUND/AIM: While blood neutrophil-to-lymphocyte ratio (NLR) has been associated with poor prognosis in NSCLC, however few studies have focused on pleural fluid white blood cell differential count. We conducted a retrospective multicenter cohort study to evaluate the predictive value of pleural NLR in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE). PATIENTS AND METHODS: From the multicenter lung cancer cohort, 134 epidermal growth factor receptor (EGFR) wild-type patients with NSCLC were selected for evaluation. Receiver operating characteristic (ROC) curve analysis was performed for pretreatment pleural NLR to determine the cut-off value for predicting disease progression within 100 days after the diagnosis.
RESULTS: The low-pleural NLR group showed significantly longer overall survival (OS) and progression free survival (PFS) compared to the high-pleural NLR group. After stratification using quartile cut-off values of pleural NLR, the correlation between risk of disease progression and pleural NLR was shown to be dose-dependent. The multivariate analysis on PFS showed that high-pleural NLR (p=0.004) was an independent predictor for shorter PFS with HR of 1.036 (1.011-1.061).
CONCLUSION: Increased pleural NLR is predictive of early disease progression in EGFR mutation wild-type NSCLC patients with MPE. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; malignant pleural effusion; pleural neutrophil-to-lymphocyte ratio

Mesh:

Year:  2020        PMID: 32606202      PMCID: PMC7439889          DOI: 10.21873/invivo.12027

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  23 in total

Review 1.  Management of malignant pleural effusions.

Authors:  V B Antony; R Loddenkemper; P Astoul; C Boutin; P Goldstraw; J Hott; F Rodriguez Panadero; S A Sahn
Journal:  Eur Respir J       Date:  2001-08       Impact factor: 16.671

2.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

3.  Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer.

Authors:  S R Walsh; E J Cook; F Goulder; T A Justin; N J Keeling
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

Review 4.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma.

Authors:  Dhanwant Gomez; Gareth Morris-Stiff; Giles J Toogood; J Peter A Lodge; K Rajendra Prasad
Journal:  J Surg Oncol       Date:  2008-05-01       Impact factor: 3.454

Review 7.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

8.  Prognostic value of pleural effusion in patients with non-small cell lung cancer.

Authors:  S Sugiura; Y Ando; H Minami; M Ando; S Sakai; K Shimokata
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.

Authors:  Andreas Carus; Howard Gurney; Val Gebski; Paul Harnett; Rina Hui; Richard Kefford; Nicholas Wilcken; Morten Ladekarl; Hans von der Maase; Frede Donskov
Journal:  J Transl Med       Date:  2013-08-15       Impact factor: 5.531

View more
  3 in total

1.  Elevation of Neutrophil-to-Lymphocyte Ratio Is a Significant Poor Prognostic Factor in Completely Resected Centrally Located Lung Squamous Cell Carcinoma.

Authors:  Takuma Tsukioka; Nobuhiro Izumi; Hiroaki Komatsu; Hidetoshi Inoue; Ryuichi Ito; Satoshi Suzuki; Noritoshi Nishiyama
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

Authors:  Jeong Uk Lim; Hye Seon Kang; Chang Dong Yeo; Ju Sang Kim; Chan Kwon Park; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

3.  A Preliminary Study on the Prognostic Impact of Neutrophil to Lymphocyte Ratio of the Bronchoalveolar Lavage Fluid in Patients with Lung Cancer.

Authors:  Woo Kyung Ryu; Yeonsook Moon; Mi Hwa Park; Jun Hyeok Lim; Young Sam Kim; Kyung-Hee Lee; Seung Min Kwak; Changhwan Kim; Hae-Seong Nam
Journal:  Diagnostics (Basel)       Date:  2021-11-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.